ESMO 2026: Tango regimen meets benchmark as Takeda-Innovent data emerge
At the ESMO 2026 congress in Madrid, Tango's combination therapy cleared a benchmark tied to Rasonque. Takeda's collaboration with Innovent also showed early returns. Anticipation for the meeting was muted after awaited Moderna and Merck cancer vaccine data leaked.
Expanded Detail
EXPANDED:
At the ESMO 2026 congress in Madrid, Tango reported that its combination treatment met a benchmark associated with Rasonque. Takeda and Innovent also offered preliminary findings from their partnership.
Expectations for the meeting were dampened after cancer vaccine data from Moderna and Merck surfaced before its
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Tango reports promising pancreatic cancer data as ESMO opens · Cancer research
ESMO 2026 abstracts spotlight Zai Lab, GSK, Merck and others · Cancer research
Key Updates From Day Two of ESMO 2026 · Cancer research
What to watch as Moderna and Merck unveil cancer vaccine results · Cancer research
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Tango combo clears Rasonque bar, Takeda's Innovent bet gets early returns, plus more from #ESMO26.” Browse more stories.